EUVIMEDEUVIMED entdecken
Multizentrische Studie

Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection

Hidenori Toyoda, Akito Nozaki, Atsushi Hiraoka, Ei Itobayashi, Haruki Uojima, Hiroshi Abe, Koichi Takaguchi, Masanori Atsukawa iD, Norio Itokawa, Kentaro Matsuura iD, Motoyuki Kojima, Toru Ishikawa und 15 weitere

Journal of Medical Virology · 2026-03 · 98 (3)

DOI: 10.1002/jmv.70865 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Medical Virology, online erschienen am 06.03.2026. Verfasst von Hidenori Toyoda und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Sustained Virologic Response, Liver Neoplasms. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The risk of developing hepatocellular carcinoma (HCC) persists in patients with cirrhosis and a sustained virologic response (SVR, the eradication of hepatitis C virus [HCV]), and therefore surveillance for HCC is recommended. However, patients with mild or no fibrosis are usually at low risk and HCC surveillance is not recommended in many guidelines. Nevertheless, some patients experience post‐SVR HCC despite having low degree liver fibrosis. We characterized the changes in liver fibrosis in patients in whom HCC developed after SVR. We performed a nationwide multicenter study, during which HCC developed in 332 of 6047 patients (5.5%) with no history of HCC who achieved SVR. FIB‐4 index, the laboratory index of liver fibrosis, was calculated at the start of anti‐HCV therapy and at a diagnosis of HCC, and the changes were characterized. Most patients who developed HCC after SVR had cirrhosis or advanced liver fibrosis (FIB‐4 index > 3.25) before anti‐HCV therapy, including some whose liver fibrosis regressed after SVR. Some patients (3.6%) without substantial fibrosis (FIB‐4 index ≤ 3.25) before anti‐HCV therapy developed HCC with the progression of liver fibrosis after SVR. Finally, 5 patients (1.6%) had mild or no fibrosis (FIB‐4 index < 1.45) both before anti‐HCV therapy and when HCC developed. Most HCCs in patients who achieve SVR develop in association with liver cirrhosis or advanced fibrosis, but some develop in livers without substantial fibrosis. In addition, post‐SVR HCC can develop in patients with mild or no fibrosis both before anti‐HCV therapy and after SVR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver CirrhosisSustained Virologic ResponseLiver NeoplasmsAntiviral AgentsHepatitis C, ChronicHumansMaleFemaleMiddle AgedAgedHepacivirusAdult

Stichwörter der Autor:innen

hepatitis C virus infectionhepatocellular carcinomaliver fibrosisrisk of liver carcinogenesissustained virologic response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
  • Gastroenterology Center, Yokohama City University Medical Center, Yokohama, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan.
  • Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

ORCID-Profile: Masanori Atsukawa, Kentaro Matsuura, Toshifumi Tada, Takashi Kumada

Zitieren

APA

Toyoda, H., Nozaki, A., Hiraoka, A., Itobayashi, E., Uojima, H., Abe, H., Takaguchi, K., Atsukawa, M., Itokawa, N., Matsuura, K., Kojima, M., Ishikawa, T., Watanabe, T., Mikami, S., Tsuji, K., Ohama, H., Tada, F., Tsutsui, A., Okubo, T., …, & Kumada, T. (2026). Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection. Journal of Medical Virology, 98(3). https://doi.org/10.1002/jmv.70865

Vancouver

Toyoda H, Nozaki A, Hiraoka A, Itobayashi E, Uojima H, Abe H, et al. Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection. Journal of Medical Virology. 2026;98(3). doi:10.1002/jmv.70865

BibTeX
@article{Toyoda2026,
  author = {Toyoda, Hidenori and Nozaki, Akito and Hiraoka, Atsushi and Itobayashi, Ei and Uojima, Haruki and Abe, Hiroshi and Takaguchi, Koichi and Atsukawa, Masanori and Itokawa, Norio and Matsuura, Kentaro and Kojima, Motoyuki and Ishikawa, Toru and Watanabe, Tsunamasa and Mikami, Shigeru and Tsuji, Kunihiko and Ohama, Hideko and Tada, Fujimasa and Tsutsui, Akemi and Okubo, Tomomi and Arai, Taeang and Nakamuta, Makoto and Imai, Michitaka and Tanaka, Kazunari and Tada, Toshifumi and Nakamura, Shinichiro and Shimada, Noritomo and Kumada, Takashi},
  title = {Changes in the Liver Fibrosis of Patients Who Develop Hepatocellular Carcinoma After a Sustained Virologic Response to Hepatitis C Virus Infection},
  journal = {Journal of Medical Virology},
  year = {2026},
  volume = {98},
  number = {3},
  doi = {10.1002/jmv.70865}
}
Kostenlos starten →